Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 110

1.

Genetic variation on 9p22 is associated with abnormal ovarian ultrasound results in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial.

Wentzensen N, Black A, Jacobs K, Yang HP, Berg CD, Caporaso N, Peters U, Ragard L, Buys SS, Chanock S, Hartge P.

PLoS One. 2011;6(7):e21731. doi: 10.1371/journal.pone.0021731. Epub 2011 Jul 7.

2.

Genetic variation in innate immunity and inflammation pathways associated with lung cancer risk.

Shiels MS, Engels EA, Shi J, Landi MT, Albanes D, Chatterjee N, Chanock SJ, Caporaso NE, Chaturvedi AK.

Cancer. 2012 Nov 15;118(22):5630-6. doi: 10.1002/cncr.27605. Epub 2012 Oct 8.

3.

Genetic variation in catechol-O-methyltransferase (COMT) and obesity in the prostate, lung, colorectal, and ovarian (PLCO) cancer screening trial.

Wang SS, Morton LM, Bergen AW, Lan EZ, Chatterjee N, Kvale P, Hayes RB, Chanock SJ, Caporaso NE.

Hum Genet. 2007 Aug;122(1):41-9. Epub 2007 May 12.

PMID:
17497175
4.

Pathologic findings following false-positive screening tests for ovarian cancer in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial.

Nyante SJ, Black A, Kreimer AR, Duggan MA, Carreon JD, Kessel B, Buys SS, Ragard LR, Johnson KA, Dunn BK, Lamerato L, Commins JM, Berg CD, Sherman ME.

Gynecol Oncol. 2011 Mar;120(3):474-9. doi: 10.1016/j.ygyno.2010.11.015. Epub 2010 Dec 7.

5.

A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2.

Song H, Ramus SJ, Tyrer J, Bolton KL, Gentry-Maharaj A, Wozniak E, Anton-Culver H, Chang-Claude J, Cramer DW, DiCioccio R, Dörk T, Goode EL, Goodman MT, Schildkraut JM, Sellers T, Baglietto L, Beckmann MW, Beesley J, Blaakaer J, Carney ME, Chanock S, Chen Z, Cunningham JM, Dicks E, Doherty JA, Dürst M, Ekici AB, Fenstermacher D, Fridley BL, Giles G, Gore ME, De Vivo I, Hillemanns P, Hogdall C, Hogdall E, Iversen ES, Jacobs IJ, Jakubowska A, Li D, Lissowska J, Lubiński J, Lurie G, McGuire V, McLaughlin J, Medrek K, Moorman PG, Moysich K, Narod S, Phelan C, Pye C, Risch H, Runnebaum IB, Severi G, Southey M, Stram DO, Thiel FC, Terry KL, Tsai YY, Tworoger SS, Van Den Berg DJ, Vierkant RA, Wang-Gohrke S, Webb PM, Wilkens LR, Wu AH, Yang H, Brewster W, Ziogas A; Australian Cancer (Ovarian) Study; Australian Ovarian Cancer Study Group; Ovarian Cancer Association Consortium, Houlston R, Tomlinson I, Whittemore AS, Rossing MA, Ponder BA, Pearce CL, Ness RB, Menon U, Kjaer SK, Gronwald J, Garcia-Closas M, Fasching PA, Easton DF, Chenevix-Trench G, Berchuck A, Pharoah PD, Gayther SA.

Nat Genet. 2009 Sep;41(9):996-1000. doi: 10.1038/ng.424. Epub 2009 Aug 2.

6.

Ovarian cancer screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial: findings from the initial screen of a randomized trial.

Buys SS, Partridge E, Greene MH, Prorok PC, Reding D, Riley TL, Hartge P, Fagerstrom RM, Ragard LR, Chia D, Izmirlian G, Fouad M, Johnson CC, Gohagan JK; PLCO Project Team.

Am J Obstet Gynecol. 2005 Nov;193(5):1630-9. Erratum in: Am J Obstet Gynecol. 2005 Dec;193(6):2183-4.

PMID:
16260202
7.

Assessing the risk of ovarian malignancy in asymptomatic women with abnormal CA 125 and transvaginal ultrasound scans in the prostate, lung, colorectal, and ovarian screening trial.

Partridge EE, Greenlee RT, Riley TL, Commins J, Ragard L, Xu JL, Buys SS, Prorok PC, Fouad MN.

Obstet Gynecol. 2013 Jan;121(1):25-31. doi: http://10.1097/AOG.0b013e3182755e14.

8.

Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial.

Prorok PC, Andriole GL, Bresalier RS, Buys SS, Chia D, Crawford ED, Fogel R, Gelmann EP, Gilbert F, Hasson MA, Hayes RB, Johnson CC, Mandel JS, Oberman A, O'Brien B, Oken MM, Rafla S, Reding D, Rutt W, Weissfeld JL, Yokochi L, Gohagan JK; Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial Project Team.

Control Clin Trials. 2000 Dec;21(6 Suppl):273S-309S.

PMID:
11189684
9.

Randomization to screening for prostate, lung, colorectal and ovarian cancers and thyroid cancer incidence in two large cancer screening trials.

O'Grady TJ, Kitahara CM, DiRienzo AG, Boscoe FP, Gates MA.

PLoS One. 2014 Sep 5;9(9):e106880. doi: 10.1371/journal.pone.0106880. eCollection 2014.

10.

Replication study for the association of seven genome- GWAS-identified Loci with susceptibility to ovarian cancer in the Polish population.

Mostowska A, Sajdak S, Pawlik P, Markowska J, Pawałowska M, Lianeri M, Jagodzinski PP.

Pathol Oncol Res. 2015 Apr;21(2):307-13. doi: 10.1007/s12253-014-9822-6. Epub 2014 Aug 31.

11.

The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial of the National Cancer Institute: history, organization, and status.

Gohagan JK, Prorok PC, Hayes RB, Kramer BS; Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial Project Team.

Control Clin Trials. 2000 Dec;21(6 Suppl):251S-272S.

PMID:
11189683
12.

Potential effect of the risk of ovarian cancer algorithm (ROCA) on the mortality outcome of the Prostate, Lung, Colorectal and Ovarian (PLCO) trial.

Pinsky PF, Zhu C, Skates SJ, Black A, Partridge E, Buys SS, Berg CD.

Int J Cancer. 2013 May 1;132(9):2127-33. doi: 10.1002/ijc.27909. Epub 2012 Nov 5.

13.

Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial.

Buys SS, Partridge E, Black A, Johnson CC, Lamerato L, Isaacs C, Reding DJ, Greenlee RT, Yokochi LA, Kessel B, Crawford ED, Church TR, Andriole GL, Weissfeld JL, Fouad MN, Chia D, O'Brien B, Ragard LR, Clapp JD, Rathmell JM, Riley TL, Hartge P, Pinsky PF, Zhu CS, Izmirlian G, Kramer BS, Miller AB, Xu JL, Prorok PC, Gohagan JK, Berg CD; PLCO Project Team.

JAMA. 2011 Jun 8;305(22):2295-303. doi: 10.1001/jama.2011.766.

PMID:
21642681
14.

Cumulative incidence of false-positive results in repeated, multimodal cancer screening.

Croswell JM, Kramer BS, Kreimer AR, Prorok PC, Xu JL, Baker SG, Fagerstrom R, Riley TL, Clapp JD, Berg CD, Gohagan JK, Andriole GL, Chia D, Church TR, Crawford ED, Fouad MN, Gelmann EP, Lamerato L, Reding DJ, Schoen RE.

Ann Fam Med. 2009 May-Jun;7(3):212-22. doi: 10.1370/afm.942.

15.

Association between genetic variants in the 8q24 cancer risk regions and circulating levels of androgens and sex hormone-binding globulin.

Chu LW, Meyer TE, Li Q, Menashe I, Yu K, Rosenberg PS, Huang WY, Quraishi SM, Kaaks R, Weiss JM, Hayes RB, Chanock SJ, Hsing AW.

Cancer Epidemiol Biomarkers Prev. 2010 Jul;19(7):1848-54. doi: 10.1158/1055-9965.EPI-10-0101. Epub 2010 Jun 15.

16.

A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24.

Goode EL, Chenevix-Trench G, Song H, Ramus SJ, Notaridou M, Lawrenson K, Widschwendter M, Vierkant RA, Larson MC, Kjaer SK, Birrer MJ, Berchuck A, Schildkraut J, Tomlinson I, Kiemeney LA, Cook LS, Gronwald J, Garcia-Closas M, Gore ME, Campbell I, Whittemore AS, Sutphen R, Phelan C, Anton-Culver H, Pearce CL, Lambrechts D, Rossing MA, Chang-Claude J, Moysich KB, Goodman MT, Dörk T, Nevanlinna H, Ness RB, Rafnar T, Hogdall C, Hogdall E, Fridley BL, Cunningham JM, Sieh W, McGuire V, Godwin AK, Cramer DW, Hernandez D, Levine D, Lu K, Iversen ES, Palmieri RT, Houlston R, van Altena AM, Aben KK, Massuger LF, Brooks-Wilson A, Kelemen LE, Le ND, Jakubowska A, Lubinski J, Medrek K, Stafford A, Easton DF, Tyrer J, Bolton KL, Harrington P, Eccles D, Chen A, Molina AN, Davila BN, Arango H, Tsai YY, Chen Z, Risch HA, McLaughlin J, Narod SA, Ziogas A, Brewster W, Gentry-Maharaj A, Menon U, Wu AH, Stram DO, Pike MC; Wellcome Trust Case-Control Consortium, Beesley J, Webb PM; Australian Cancer Study (Ovarian Cancer); Australian Ovarian Cancer Study Group; Ovarian Cancer Association Consortium (OCAC), Chen X, Ekici AB, Thiel FC, Beckmann MW, Yang H, Wentzensen N, Lissowska J, Fasching PA, Despierre E, Amant F, Vergote I, Doherty J, Hein R, Wang-Gohrke S, Lurie G, Carney ME, Thompson PJ, Runnebaum I, Hillemanns P, Dürst M, Antonenkova N, Bogdanova N, Leminen A, Butzow R, Heikkinen T, Stefansson K, Sulem P, Besenbacher S, Sellers TA, Gayther SA, Pharoah PD; Ovarian Cancer Association Consortium (OCAC).

Nat Genet. 2010 Oct;42(10):874-9. doi: 10.1038/ng.668. Epub 2010 Sep 19.

17.

Analysis of serial ovarian volume measurements and incidence of ovarian cancer: implications for pathogenesis.

Bodelon C, Pfeiffer RM, Buys SS, Black A, Sherman ME.

J Natl Cancer Inst. 2014 Sep 13;106(10). pii: dju262. doi: 10.1093/jnci/dju262. Print 2014 Oct.

18.

Dietary carbohydrate, glycemic index, glycemic load, and risk of prostate cancer in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO) cohort.

Shikany JM, Flood AP, Kitahara CM, Hsing AW, Meyer TE, Willcox BJ, Redden DT, Ziegler RG.

Cancer Causes Control. 2011 Jul;22(7):995-1002. doi: 10.1007/s10552-011-9772-1. Epub 2011 May 7.

19.

A Cross-Cancer Genetic Association Analysis of the DNA Repair and DNA Damage Signaling Pathways for Lung, Ovary, Prostate, Breast, and Colorectal Cancer.

Scarbrough PM, Weber RP, Iversen ES, Brhane Y, Amos CI, Kraft P, Hung RJ, Sellers TA, Witte JS, Pharoah P, Henderson BE, Gruber SB, Hunter DJ, Garber JE, Joshi AD, McDonnell K, Easton DF, Eeles R, Kote-Jarai Z, Muir K, Doherty JA, Schildkraut JM.

Cancer Epidemiol Biomarkers Prev. 2016 Jan;25(1):193-200. doi: 10.1158/1055-9965.EPI-15-0649. Epub 2015 Dec 4.

20.

Characterization of 9p24 risk locus and colorectal adenoma and cancer: gene-environment interaction and meta-analysis.

Kocarnik JD, Hutter CM, Slattery ML, Berndt SI, Hsu L, Duggan DJ, Muehling J, Caan BJ, Beresford SA, Rajkovic A, Sarto GE, Marshall JR, Hammad N, Wallace RB, Makar KW, Prentice RL, Potter JD, Hayes RB, Peters U.

Cancer Epidemiol Biomarkers Prev. 2010 Dec;19(12):3131-9. doi: 10.1158/1055-9965.EPI-10-0878. Epub 2010 Oct 26.

Supplemental Content

Support Center